HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure

NCT06375317 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma

Interventions

DRUG: PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets

Sponsor

Yehua Shen